Caris Life Sciences, Inc. (CAI) KPIs and segments
Close on Nov 18, 2026Market cap $5.51BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Caris Life Sciences · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Caris Life Sciences: 38 chỉ số vận hành, trong đó có Clinical Cases Completed, Full-Year Clinical Therapy Selection Volume Growth và Full-Year Total Revenue Guidance — Low, lấy từ 526 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cost of services - Molecular profiling services($M) | 252 | 211 | 282 | 208 | 163 | 114 | 94.4 | 93.8 | 87.7 | ||||
Cost of services - Pharma research and development services($M) | 11.5 | 5.37 | 10.8 | 9.25 | 18.5 | 6.83 | 35.5 | 7.82 | 12.4 | ||||
United States($M) | 262 | 214 | 291 | 214 | 178 | 118 | 127 | 99.4 | 97.4 | ||||
International($M) | 2.14 | 2.34 | 1.65 | 3.28 | 3.22 | 2.48 | 3.29 | 2.22 | 2.67 | ||||
Cost of services - Molecular profiling services($M) | 171 | 138 | 213 | 141 | 97.6 | 53.2 | 38.5 | 39.0 | 28.2 | ||||
Cost of services - Pharma research and development services($M) | 8.67 | 3.43 | 7.95 | 6.90 | 16.1 | 3.88 | 32.2 | 5.42 | 9.33 | ||||
Clinical Cases Completed4 | 61,500 | 59,200 | 52,800 | 52,700 | 50,763 | 50,032 | 45,858 | 44,006 | 42,956 | 40,998 | 34,902 | ||
Clinical Case Volume YoY Growth(%) | 21.0% | 18.0% | 15.0% | 20.0% | 18.2% | 22.0% | 31.4% | ||||||
MI Profile Tissue-Based Therapy Selection Cases [legacy through Q2 2026] | 48,300 | 43,600 | 44,150 | 43,226 | 42,886 | 40,048 | 38,650 | 38,409 | 36,426 | 33,095 | |||
Caris Assure Blood-Based Therapy Selection Cases [legacy through Q2 2026] | 10,700 | 9,200 | 8,550 | 7,537 | 7,146 | 5,810 | 5,356 | 4,547 | 4,572 | 1,807 | |||
Total Cases Completed (Clinical, Biopharma & External Research) [legacy through Q1 2025]1 | 47,300 | 36,500 | |||||||||||
Biopharma & External Research Cases [legacy through Q1 2025] | 1,500 | 1,600 | |||||||||||
Full-Year Clinical Therapy Selection Volume Growth Guidance — Low(%)1 | 20.0% | 20.0% | 20.0% | 20.0% | 21.0% | 19.0% | |||||||
Full-Year Clinical Therapy Selection Volume Growth Guidance — High(%) | 20.0% | 20.0% | 20.0% | 20.0% | 22.0% | 21.0% | |||||||
Full-Year Total Revenue Guidance — Low($M)3 | 1,040 | 1,030 | 1,000 | 1,000 | 720 | 675 | |||||||
Full-Year Total Revenue Guidance — High($M) | 1,050 | 1,040 | 1,020 | 1,020 | 730 | 685 | |||||||
Full-Year Total Revenue YoY Growth Guidance — Low(%) | 28.0% | 27.0% | 23.0% | 23.0% | 75.0% | 64.0% | |||||||
Full-Year Total Revenue YoY Growth Guidance — High(%) | 29.0% | 28.0% | 26.0% | 26.0% | 77.0% | 66.0% | |||||||
Medicare Share of Molecular Profiling Services Revenue(%) | 36.9% | 38.9% | 41.2% | 39.4% | 49.7% | 54.3% | 38.6% | 40.1% | 40.5% | ||||
Major Payer 1 — Share of Total Revenue(%)4 | 35.2% | 37.3% | 40.2% | 37.7% | 44.7% | 51.2% | 35.6% | 35.1% | |||||
Major Payer 2 — Share of Total Revenue(%) | 12.1% | 12.6% | 17.4% | 21.2% | 14.9% | 13.5% | 17.3% | 13.5% | |||||
Major Payer 3 — Share of Total Revenue(%) | 13.9% | 15.6% | 12.8% | 12.9% | 11.5% | ||||||||
Major Payer 1 — Share of Period-End Accounts Receivable(%) | 20.7% | 23.5% | 25.0% | 18.4% | 50.8% | 68.3% | 16.1% | ||||||
Major Payer 2 — Share of Period-End Accounts Receivable(%) | 21.8% | 23.6% | 33.6% | 22.6% | 19.3% | ||||||||
Prior-Period Cash Collection & Reimbursement Revenue Adjustments($M) | 17.2 | 23.6 | 10.3 | 10.2 | 38.3 | 12 | 3.90 | 1 | 6.80 | -3.90 | -3.90 | ||
Remaining Performance Obligations (RPO — Contracts > 1 Year)($M)2 | 10.8 | 17.2 | 7.60 | 6.50 | 9.10 | 2.60 | 7.10 | 5.80 | |||||
Unbilled Contract Receivables($M) | 3 | 5.90 | 3.70 | 7.20 | 9.90 | 11.2 | 1.60 | 4.60 | |||||
Current Contract Liabilities (Deferred Revenue)($M) | 18.4 | 20.5 | 25.0 | 24.5 | 2.79 | 5.34 | 7.66 | 7.47 | |||||
Cumulative Scientific Output (Manuscripts, Abstracts & Posters) [legacy through Q1 2025]2 | 1,054 | ||||||||||||
Cumulative Peer-Reviewed Manuscripts [legacy through Q1 2025] | 388 | ||||||||||||
Cumulative Conference Abstracts, Posters & Presentations [legacy through Q1 2025] | 666 | ||||||||||||
Property and Equipment, Gross($M)7 | 360 | 347 | 328 | 304 | 304 | 303 | 297 | 296 | |||||
Laboratory & Sequencing Equipment, Gross($M) | 141 | 138 | 124 | 106 | 108 | 109 | 104 | 104 | |||||
Computer Equipment & Software, Gross($M) | 71.7 | 82.7 | 80.6 | 76.4 | 75.8 | 74.8 | 77.1 | 73.3 | |||||
Laboratory & Office Leasehold Improvements, Gross($M) | 67.8 | 64.8 | 64.2 | 63.8 | 63.5 | 63.3 | 63.3 | 63.0 | |||||
Capitalized Internal-Use Software Development, Gross($M) | 48.4 | 31.6 | 29.5 | 27.9 | 27.1 | 26.3 | 22.6 | 25.9 | |||||
Aircraft & Leased Equipment, Gross($M) | 21.8 | 21.4 | 21.4 | 21.4 | 21.3 | 21.3 | 21.3 | 21.3 | |||||
Furniture & Fixtures, Gross($M) | 8.84 | 8.41 | 8.41 | 8.37 | 8.30 | 9.13 | 9.11 | 9.11 | |||||
Accumulated Depreciation & Amortization($M) | 258 | 251 | 246 | 241 | 240 | 242 | 236 | 229 | |||||
Laboratory Sequencing Reagents & Supplies Inventory($M) | 138 | 124 | 76.3 | 63.6 | 49.3 | 40.6 | 36.6 | 39.6 | |||||
Operating Lease Liabilities — Non-Current($M)1 | 63.5 | 52.9 | 43.6 | 42.3 | 43.8 | 38.0 | 37.1 | 38.7 | |||||
Operating Lease Liabilities — Current($M) | 6.29 | 6.37 | 5.84 | 6.36 | 6.45 | 7.29 | 6.02 | 6.08 | |||||
Consolidated Gross Profit($M)1 | 182 | 180 | 141 | 221 | 148 | 114 | 57.1 | 70.7 | 44.4 | 37.6 | 26.1 | ||
Consolidated Gross Margin(%) | 66.0% | 68.0% | 65.0% | 75.0% | 68.0% | 62.7% | 47.0% | 54.0% | 43.7% | 37.5% | |||
Adjusted EBITDA($M) | 44.4 | 55.7 | 26.2 | 106 | 51.2 | 16.7 | -36.2 | -23 | -45.6 | -50.9 | -70.1 | ||
Stock-Based Compensation Expense — Total($M)5 | 18.5 | 22.2 | 15.9 | 13.4 | 13.7 | 28.3 | 14.7 | 4.98 | 4.72 | 4.48 | |||
SBC — Cost of Services (Molecular Profiling)($M) | 0.67 | 1.72 | 1.32 | 1.14 | 1.10 | 0.88 | 0.47 | 0.43 | 0.41 | 0.40 | |||
SBC — Cost of Services (Pharma R&D)($M) | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | |||
SBC — Selling & Marketing($M) | 4.50 | 4.99 | 3.82 | 3.03 | 3.32 | 1.99 | 1.24 | 1.12 | 1.09 | 0.97 | |||
SBC — General & Administrative($M) | 9.71 | 10.9 | 7.44 | 6.25 | 6.41 | 22.4 | 10.6 | 2.30 | 2.15 | 2.05 | |||
SBC — Research & Development($M) | 3.61 | 4.59 | 3.28 | 2.95 | 2.80 | 3.03 | 2.35 | 1.11 | 1.07 | 1.06 | |||
Stock Options Outstanding(M)3 | 16.3 | 21.3 | 21.7 | 21.9 | 22.7 | 23.5 | 24.1 | 21.8 | |||||
Stock Options Outstanding — Weighted-Average Exercise Price($) | 11.33 | 10.15 | 10.19 | 10.23 | 10.38 | 10.33 | 10.18 | 9.06 | |||||
Stock Options Outstanding — Aggregate Intrinsic Value($M) | 329 | 176 | 171 | 367 | 450 | 349 | 361 | 226 | |||||
Unrecognized SBC Expense — Unvested Stock Options($M)1 | 27.4 | 34.3 | 42 | 51.5 | |||||||||
Unrecognized SBC Weighted-Average Recognition Period — Options(năm) | 2.4 | 2.3 | 2.5 | 2.8 | |||||||||
Unvested RSUs & PSUs Outstanding(M)2 | 8.07 | 8.16 | 9.27 | 4.49 | 0.76 | ||||||||
Unvested RSUs & PSUs — Weighted-Average Grant-Date Fair Value($) | 20 | 19.91 | 20.16 | 21.18 | 18.19 | ||||||||
Unrecognized SBC Expense — Unvested RSUs & PSUs($M)1 | 125 | 143 | 163 | 81.6 | |||||||||
Unrecognized SBC Weighted-Average Recognition Period — RSUs & PSUs(năm) | 2.8 | 3.0 | 3.2 | 3.3 | |||||||||
Contractual Debt Interest Expense (Excl. Discount Amortization)($M)1 | 8.93 | 8.92 | 10.2 | 10.7 | 11.0 | 11.5 | 10.8 | 11.4 | 12.0 | 11.9 | |||
Amortization of Debt Discounts & Issuance Costs($M) | 0.31 | 0.30 | 2.62 | 0.60 | 2.46 | 7.75 | 1.94 | 1.91 | 1.83 | 1.73 | |||
NCBI PubMed — Peer-Reviewed Publications Affiliated with Caris Life Sciences | 30 | 31 | 38 | 26 | 39 | 31 | 34 | 39 | 23 | 23 | 24 | 19 | |
U.S. Medical & Diagnostic Laboratories Industry Revenue (Census QSS NAICS 6215, NSA)($M) | 20,528 | 19,569 | 19,997 | 19,677 | 19,718 | 18,722 | 19,104 | 18,893 | 18,483 | 17,963 | 17,943 | ||
U.S. Personal Consumption Expenditures — Health Care Services (SAAR)($M) | 3,858,700 | 3,790,300 | 3,699,900 | 3,667,000 | 3,614,900 | 3,529,800 | 3,464,700 | 3,417,800 | 3,358,200 | 3,288,200 | 3,244,400 | 3,159,400 | |
Tempus AI, Inc. (TEM) — Total Revenue($M)1 | 412 | 382 | 348 | 367 | 334 | 315 | 256 | 201 | 181 | 166 | 146 | 148 | |
Tempus AI, Inc. (TEM) — Operating Income (Loss)($M) | -57 | -76 | -85 | -61 | -61 | -62 | -69 | -51 | -54 | -533 | -53 | -52 | |
Natera, Inc. (NTRA) — Total Revenue($M)1 | 794 | 753 | 697 | 665 | 592 | 547 | 502 | 476 | 440 | 413 | 368 | 311 | |
Natera, Inc. (NTRA) — Operating Income (Loss)($M) | -68 | -76 | -94 | -23 | -98 | -110 | -79 | -65 | -39 | -44 | -74 | -85 | |
Guardant Health, Inc. (GH) — Total Revenue($M)1 | 361 | 335 | 302 | 281 | 265 | 232 | 203 | 202 | 191 | 177 | 168 | 155 | |
Guardant Health, Inc. (GH) — Operating Income (Loss)($M) | -133 | -129 | -121 | -121 | -99 | -106 | -111 | -126 | -117 | -101 | -100 | -198 | |
Exact Sciences Corp. (EXAS) — Total Revenue($M)1 | 878 | 851 | 811 | 707 | 713 | 709 | 699 | 638 | 647 | ||||
Exact Sciences Corp. (EXAS) — Operating Income (Loss)($M) | -83 | -26 | -2 | -96 | -876 | -39 | -26 | -107 | -68 | ||||
Veracyte, Inc. (VCYT) — Total Revenue($M)1 | 152 | 150 | 139 | 141 | 132 | 130 | 114 | 119 | 116 | 114 | 97 | 98 | |
Veracyte, Inc. (VCYT) — Operating Income (Loss)($M) | 17 | 23 | 23 | 37 | 23 | -5 | 3 | 4 | 12 | 5 | -5 | -36 | |
Myriad Genetics, Inc. (MYGN) — Total Revenue($M)1 | 203 | 191 | 200 | 210 | 206 | 213 | 196 | 211 | 213 | 212 | 202 | 197 | |
Myriad Genetics, Inc. (MYGN) — Operating Income (Loss)($M) | -40 | -39 | -31 | -6 | -23 | -329 | -29 | -39 | -20 | -36 | -28 | -31 | |
Quest Diagnostics Inc. (DGX) — Total Revenue($M)1 | 3,097 | 3,043 | 2,895 | 2,806 | 2,816 | 2,761 | 2,652 | 2,621 | 2,488 | 2,397 | 2,366 | 2,288 | |
Quest Diagnostics Inc. (DGX) — Operating Income (Loss)($M) | 479 | 459 | 399 | 386 | 386 | 438 | 346 | 361 | 330 | 355 | 300 | 267 | |
Labcorp Holdings Inc. (LH) — Total Revenue($M)1 | 3,810 | 3,731 | 3,538 | 3,516 | 3,564 | 3,527 | 3,345 | 3,329 | 3,282 | 3,221 | 3,177 | 3,033 | |
Labcorp Holdings Inc. (LH) — Operating Income (Loss)($M) | 402 | 452 | 381 | 268 | 397 | 394 | 326 | 216 | 254 | 295 | 321 | -123 | |
Total Revenue($M)4 | 275 | 264 | 216 | 293 | 217 | 181 | 121 | 130 | 102 | 100 | |||
Total Costs and Operating Expenses($M) | 256 | 237 | 211 | 205 | 184 | 199 | 179 | 167 | 163 | 167 | |||
Research & Development Expense($M) | 33.8 | 32.4 | 31.3 | 31.8 | 21.6 | 25 | 23.1 | 27.1 | 27.6 | 24.8 | |||
Selling & Marketing Expense($M) | 59.9 | 53.8 | 45 | 44.2 | 41.3 | 42.3 | 39.8 | 37.5 | 36.8 | 38.7 | |||
General & Administrative Expense($M) | 69.3 | 66.5 | 59.7 | 56.5 | 52 | 64.4 | 52.1 | 43.1 | 40.9 | 41.1 | |||
Operating Income (Loss)($M)1 | 19.3 | 26.9 | 5.30 | 88.4 | 32.6 | -18 | -58 | -37 | -60.8 | -67 | |||
Net Income (Loss)($M) | 15.2 | -0.60 | -0.50 | 82 | 24.3 | -71.8 | -103 | -36.9 | -67.7 | -66.2 | |||
Operating Cash Flow($M)2 | -22.2 | 28.5 | 32.9 | 44.8 | 62.4 | 7.30 | -31.3 | -38.9 | -69.4 | ||||
Capital Expenditures & Capitalized Software($M) | 17.5 | 22.1 | 10.3 | 5.10 | 7.10 | 1.40 | 2.70 | 2.30 | 1.80 | ||||
Common Stock Repurchases (Cash Flow)($M) | 10.0 | 21.4 | -0 | 0.09 | -0 | -0 | 0.02 | -0 | -0 | ||||
Total Assets($M)4 | 1,256 | 1,230 | 1,162 | 1,126 | 985 | 955 | 344 | ||||||
Short-Term Marketable Securities($M) | 102 | 102 | 2.30 | 2.30 | 2.30 | 2.20 | 2.20 | ||||||
Accounts Receivable, Net($M) | 133 | 117 | 90.5 | 112 | 26.7 | 50.9 | 88.2 | ||||||
Property & Equipment, Net($M) | 102 | 95.7 | 82.7 | 63.2 | 64 | 61.3 | 67.8 | ||||||
Total Shareholders' Equity (Deficit)($M) | 640 | 592 | 594 | 577 | 478 | 453 | -2,600 | -2,499 | -2,442 | -2,360 | -2,275 | -2,145 | |
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal Calendar: Caris Life Sciences, Inc. operates on a calendar fiscal year ending December 31 (Q1 ends March 31, Q2 ends June 30, Q3 ends September 30, Q4 ends December 31). Latest reported company quarter is Q3 2026 (ended September 30, 2026, filed November 4, 2026 on Form 8-K and Form 10-Q) and latest completed fiscal year is FY2025 (ended December 31, 2025, filed March 3, 2026 on Form 10-K). Monthly BLS macro benchmarks extend through October 2026 (2026-10).
- Q3 2026 Clinical Case Reporting Transition: Through Q2 2026, Caris disaggregated clinical cases into MI Profile (tissue-based therapy selection) and Caris Assure (blood-based therapy selection). Following the Q2–Q3 2026 commercial launches of Caris Detect (MCED), Caris ChromoSeq (myeloid WGS/WTS), Caris MI Clarity (digital AI pathology), and Caris Assure Therapy Response Monitoring, management consolidated reporting into unified Clinical Cases Completed starting Q3 2026; platform breakdowns through Q2 2026 are preserved as legacy child rows.
- Standalone Parent-Company Financials: Caris files consolidated US GAAP financial statements and operates through wholly-owned domestic laboratory subsidiaries (Caris MPI, Inc. and Caris Science, Inc.) without standalone parent-only operating financial statements; consolidated-minus-standalone subtraction does not apply.
- Derivation & Verification Policy: All values represent published company, peer XBRL, or government/scientific database point figures, plus permitted period splits from cumulative disclosures (Q4 = full year − nine months and quarterly cash flow = year-to-date − prior year-to-date). Figures disclosed solely with bound qualifiers ('surpassed', 'more than', 'over') are excluded.
Không hiện vì thiếu các kỳ gần đây (10)
- Clinical Average Selling Price (ASP per Case) — Total, MI Profile & Caris Assure ($/Case): Formal quarterly ASP table was published only in Q2 2025 ($3,256 total; $3,379 MI Profile; $2,519 Caris Assure) and Q3 2025 ($4,089 total; $4,273 MI Profile; $3,034 Caris Assure) Form 8-K releases (2 consecutive quarters) before table discontinuation in Q4 2025; fails the 3-consecutive-quarter rule and implied ASP calculation is not permitted.
- Cumulative Clinico-Genomic Database Profiles (Total, Matched, Whole Transcriptome & Whole Exome): Quarterly Form 8-K milestones ('Surpassed 1,200,000 total profiles and 845,000 total matched profiles... More than 849,000 Whole Transcriptome and 796,000 Whole Exome profiles' as of September 30, 2026) use upper-bound qualifiers ('Surpassed', 'More than') rather than exact point counts.
- Total Oncology & WES/WTS Tests Performed per Quarter: Disclosed only with lower-bound qualifiers ('over 358,000 total oncology tests' in Q3 2026; 'over 114,000 WES/WTS tests with over 345,000 total tests' in Q2 2026).
- Share Repurchase Program — Monthly/Quarterly Shares Repurchased, Average Price Paid & Remaining Authorization ($72.1M at Q3 2026): Authorized June 8, 2026 ($100.0M program), so only 2 quarterly periods (Q2 2026: 1,000,000 shares at $17.91; Q3 2026: 514,525 shares at $19.43) exist to date; fails 3-quarter continuity.
- Major Payer 3 — Share of Period-End Accounts Receivable (%): Exceeded the 10% disclosure threshold in only 2 consecutive quarters (Q2 2026: 11.2%; Q3 2026: 14.2%).
- Total Employees / Full-Time Headcount (1,769 as of March 31, 2025; 1,846 as of December 31, 2025): Caris completed its IPO in June 2025 and has filed only 1 annual Form 10-K (FY2025) to date; annual-only series require 2 consecutive fiscal years.
- Leased Clinical Laboratory, R&D & Corporate Square Footage by Location (Phoenix Tissue Lab 66,000 sq ft, Phoenix Blood Lab 35,500 sq ft, Tempe R&D Lab 59,000 sq ft, Irving HQ 30,500 sq ft, Irving Build-Out 114,500 sq ft): Reported as of March 31, 2025 and December 31, 2025 (1 completed fiscal year).
- Owned & Exclusively In-Licensed Patent Portfolio Counts (189 owned patents and 101 pending applications across Molecular Profiling & Pharma R&D as of December 30, 2025): Only 1 completed fiscal year (FY2025) post-IPO.
- ClinicalTrials.gov Registered Studies Mentioning Caris Platforms (10 studies total): Sparse annual/quarterly start dates (FY2019, FY2023, FY2026) without consecutive multi-period continuity.
- Static One-Time Assay & Clinical Study Parameters (23,000 DNA genes, 61,000 RNA transcripts, 40,000x sequencing depth, ~600M RNA reads, ACHIEVE-1, GPSai, FOLFIRSTai, HERO 248,606 H&E slides, and IPO offering share/proceeds terms): Non-time-series product specifications or one-off transaction disclosures.
Dữ liệu cập nhật 2026-11-16.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Clinical Molecular Profiling Volume & Guidance (Key #1)
Payer Mix, Reimbursement True-Ups & Contract Backlog (Key #2)
- Medicare Share of Molecular Profiling Services Revenue (%)9 kỳ
- Major Payer 1 — Share of Total Revenue (%)8 kỳ
- Prior-Period Cash Collection & Reimbursement Revenue Adjustments ($M)11 kỳ
- Remaining Performance Obligations (RPO — Contracts > 1 Year) ($M)8 kỳ
- Molecular Profiling YoY Revenue Bridge — MI Profile ASP & Payer Mix Impact ($M)2 kỳ
Precision Oncology Alliance (POA) & Scientific Ecosystem
Laboratory, Sequencing & Compute Infrastructure
Gross Margin, Adjusted EBITDA, SBC & Debt Financing
External Regulatory, Scientific & Macro Industry Benchmarks
- NCBI PubMed — Peer-Reviewed Publications Affiliated with Caris Life Sciences15 kỳ
- U.S. FDA OpenFDA — Caris Premarket Approval (PMA) Decisions2 kỳ
- U.S. Medical & Diagnostic Laboratories Industry Revenue (Census QSS NAICS 6215, NSA) ($M)34 kỳ
- U.S. Producer Price Index — Medical Laboratories (BLS PPI NAICS 621511) (×)106 kỳ
- U.S. Consumer Price Index — Medical Care Services (BLS CPI) (×)105 kỳ
- U.S. Outpatient & Diagnostic Care Centers Employment (Thousands, SA)106 kỳ
- U.S. Personal Consumption Expenditures — Health Care Services (SAAR) ($M)35 kỳ
External Precision Oncology & Clinical Laboratory Peer Benchmarks
- Tempus AI, Inc. (TEM) — Total Revenue ($M)14 kỳ
- Natera, Inc. (NTRA) — Total Revenue ($M)27 kỳ
- Guardant Health, Inc. (GH) — Total Revenue ($M)27 kỳ
- Exact Sciences Corp. (EXAS) — Total Revenue ($M)24 kỳ
- Veracyte, Inc. (VCYT) — Total Revenue ($M)27 kỳ
- Myriad Genetics, Inc. (MYGN) — Total Revenue ($M)27 kỳ
- Quest Diagnostics Inc. (DGX) — Total Revenue ($M)27 kỳ
- Labcorp Holdings Inc. (LH) — Total Revenue ($M)27 kỳ
Consolidated Financial Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Caris Life Sciences
- SEC Form 10-Q (2026Q3, filed 2026-11-04) ↗
- SEC Form 10-K — FY2025 (filed 2026-03-03) ↗
- SEC Form 10-K (2025FY, filed 2026-03-03) ↗
- SEC Form 8-K Ex 99.1 — Q3 2026 Financial Results (filed 2026-11-04) ↗
- SEC Form 10-Q (0002019410-26-000069, filed 2026-11-04) ↗
- SEC Form 10-K (0002019410-26-000016, filed 2026-03-03) ↗
- SEC Form 10-Q — Q3 2026 (filed 2026-11-04) ↗
- SEC Form 424B4 IPO Prospectus Embedded Charts (filed 2025-06-20) ↗
- U.S. National Library of Medicine — NCBI PubMed E-utilities API ↗
- U.S. Food and Drug Administration — OpenFDA Premarket Approval (PMA) Database ↗
- U.S. Census Bureau QSS / FRED (REV6215TAXABL144QNSA) ↗
- BLS / FRED (PCU621511621511) ↗
See a number that looks wrong?